CN113134003A - Application of lamivudine in preparation of medicine for treating Alzheimer's disease - Google Patents
Application of lamivudine in preparation of medicine for treating Alzheimer's disease Download PDFInfo
- Publication number
- CN113134003A CN113134003A CN202110514200.9A CN202110514200A CN113134003A CN 113134003 A CN113134003 A CN 113134003A CN 202110514200 A CN202110514200 A CN 202110514200A CN 113134003 A CN113134003 A CN 113134003A
- Authority
- CN
- China
- Prior art keywords
- mice
- group
- lamivudine
- disease
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 23
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title claims abstract description 13
- 229960001627 lamivudine Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 238000011282 treatment Methods 0.000 claims description 21
- 238000011161 development Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 45
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 21
- 230000000971 hippocampal effect Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000003993 interaction Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 9
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 102000017919 ADRB2 Human genes 0.000 description 8
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003446 ligand Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 108091008611 Protein Kinase B Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000013042 tunel staining Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000004634 pharmacological analysis method Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000005257 cortical tissue Anatomy 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 101150049386 MMP3 gene Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 101100134743 Rattus norvegicus Oas1a gene Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010201 enrichment analysis Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101150035628 Serpine1 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008812 hippocampal apoptosis Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000034420 neuronal signal transduction Effects 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of novel medicaments, relates to application of lamivudine in preparation of medicaments for treating Alzheimer disease, and simultaneously provides a medicament for treating Alzheimer disease, wherein the main active component of the medicament is lamivudine; provides a brand new idea for treating the Alzheimer disease, widens the selection field for treating the Alzheimer disease, and also makes a contribution to the further development of lamivudine.
Description
Technical Field
The invention belongs to the field of novel medicines, relates to application of lamivudine in preparation of a medicine for treating Alzheimer disease, and simultaneously provides a medicine for treating Alzheimer disease.
Background
Alzheimer's Disease (AD) is a neurodegenerative disease, which is common in older people over 65 years of age. Irreversible damage to the brain, memory and physical function impairment occur in brain regions of part of the brain of AD patients. By 2020, more than 1000 million AD patients exist in China. The onset of AD is latent, the course of disease is long, and once the disease occurs, the disease is extremely difficult to reverse. The pathogenesis of AD is complex, and studies on its pathogenesis and prevention mechanism are actively conducted in the medical field, but the actual cause of the disease is still unclear. Unfortunately, advances in clinical trials for the treatment of AD have been limited, whether as new drug candidates or as yet marketed other disease treatment drugs.
Lamivudine (Lamivudine), also known as 3TC, is widely accepted as a nucleoside analog, is the most representative nucleoside analog with the best curative effect in clinical application at present, and is generally used for treating hepatitis b. The past research is only limited to the pharmacological action of resisting virus or resisting aging, and the research report of the action of 3TC in preparing the medicament for treating the Alzheimer disease is not available at present.
It is clear that finding new drug therapeutic targets and new therapeutic approaches for treating alzheimer's disease is a very urgent task.
Disclosure of Invention
The invention mainly relates to application of lamivudine in preparing a medicament for treating Alzheimer disease, and simultaneously provides a medicament for treating Alzheimer disease, wherein the main active component of the medicament is lamivudine; provides a brand new idea for treating the Alzheimer disease, widens the selection field for treating the Alzheimer disease, and also makes a contribution to the further development of lamivudine.
The inventor proves through experiments that:
after the administration of 3TC through gastric gavage on SAMP8 of an AD model mouse, the memory and learning capacity of an SAMP8 mouse are improved, and the inventor finds that 3TC can reduce the number of dead neurons in the hippocampal brain region of the SAMP8 mouse and can reverse the tendency of excessive rise of transposon LINE-1 and type 1 interferon reaction, aging-related secretion phenotype and AD-related pathogenic gene mRNA level in the hippocampal brain and cortical tissues of the SAMP8 mouse.
Results of network pharmacological analysis and in vitro experimental validation against 3TC indicate that 3TC can act by activating estrogen, PI3K/Akt and neuroactive ligand-receptor interaction signaling pathways. The results show that the 3TC can obviously improve AD symptoms and brain pathological injury through inhibiting inflammation, apoptosis and other ways, can be developed as a new anti-AD medicament, and provides a new means and way for treating cognitive decline and neuron injury caused by AD.
The invention has the beneficial effects that: 3TC can alleviate memory and learning decline and neuronal damage caused by AD. The invention provides a new target for preparing the medicament for treating AD, and applies 3TC to the development process of the medicament related to AD so as to prepare better treatment medicaments. The invention provides a brand new thought for the existing medicine for treating the neuron damage caused by AD, widens the selection field for treating AD, and also makes a contribution to the development of the technical field.
Drawings
FIG. 1 is a graph showing the results of improving the cognitive performance of SAMP8 mice by 3TC, using the Morris water maze test as an evaluation measure, and the Escape latency(s), the Time ratio in the target quadrant (Time in the target quadrant,%), the Number of times of crossing the platform (Number of crossing the platform), and the Time to reach the target(s) as evaluation indicators, as follows:
in the figure, A is a locus diagram of the platform found after the positioning navigation test of the 5 th day and the water enters from the second quadrant of each group of mice, the 3TC treatment group finds the platform in a shorter route than that of the untreated group,
b is a quantitative graph of the escape latency of each group of mice in a positioning navigation test every day, the escape latency of the 3 TC-treated group of mice is shorter than that of the untreated group of mice,
c is a quantitative graph of swimming speed of each group of mice in the first five days of training,
d is a trace plot of mice in a space exploration experiment, 3TC treated mice were more inclined to swim in the target quadrant than untreated mice,
e is the percentage of the total time of each group in the target quadrant of the space exploration experiment, the time of the 3TC treated mice in the target quadrant is longer than that of untreated mice,
f is the frequency of each group of mice walking through the platform in the space exploration experiment, the frequency of the 3TC treatment group of mice crossing the target platform is more than that of the untreated mice,
g is the time to target for each group of mice, the 3TC treated group of mice reached the target in a shorter time than untreated mice;
fig. 2 is a schematic diagram of the 3TC experimental results related to the reduction of the neuronal damage in the hippocampal region of the brain of the SAMP8 mouse, the tissue staining (HE staining, niemann staining and TUNEL staining) of the paraffin section of the brain is used as an evaluation means, the neuronal cell morphology in the hippocampal region, the number of healthy cells positive to niemann staining and the number of apoptotic cells positive to TUNEL staining are used as evaluation indexes, and the results are as follows:
in the figure, A is an image of HE staining of hippocampal areas of brains of all groups of mice, and the condition of disordered arrangement and loss of neuron cells of hippocampal areas of the mice after 3TC treatment is improved;
b and C are images and quantitative images of Neisseria staining of hippocampal brain of each group of mice, and healthy neuron cytosis of hippocampal region of mice after 3TC treatment;
d and E are images and quantitative graphs of TUNEL staining of hippocampal regions of brains of each group of mice, and apoptotic cells of hippocampal regions of mice are reduced after 3TC treatment;
FIG. 3 is a diagram showing mRNA levels of transposon LINE-1(L1-ORF1, L1-ORF2), type 1 interferon response (Ifna, Irf7, Oas1), senescence-associated secretory phenotype (Il6, Mmp3, Pai1) and AD-associated pathogenic gene (PS-1, APP) in the brain and hippocampal tissues of each group of mice, in which real-time fluorescent quantitative PCR was used as an evaluation means and the mRNA level of the relevant gene was used as an evaluation index;
as can be seen, 3TC reduces the mRNA levels of related markers in hippocampus (A) and cortex (B) of SAMP8 mice;
FIG. 4 is a network diagram of protein interaction nodes of 3TC action targets collected based on a public database, and 32 core targets of 3TC are screened out according to node Degree (hierarchy analysis of nodes) to serve as the most potential target proteins;
a is a network diagram of interaction of all target proteins based on data mining, and the left side is a screened core gene;
b is a protein interaction graph of the core gene, and the interaction relation among all targets of the 3TC can be known from the graph;
FIG. 5A is a Gene Ontology (GO) enrichment analysis diagram of a 3TC core target; b is KEGG (Kyoto Encyclopedia of Genes and genomes) pathway analysis diagram; c, screening out marker proteins related to Estrogen (EGFR), PI3K/Akt (pAKT1) and a neuroactive ligand-receptor interaction (ADRB2) signal channel from the protein, and carrying out 3 TC-target molecule docking simulation diagram;
FIG. 6 is a graph showing the results of in vitro experimental validation of the pharmacological analysis of the network, Formaldehyde (FA) induced damage of the neuronal cell LINE HT22, wherein A is immunofluorescence detecting the expression of LINE-1ORF1p in the control, FA and FA +3TC groups, B is the quantification of immunofluorescence analysis, C is the quantification of viable neurons per field of view for each group, D is Western blot detecting EGFR, p-AKT1 and ADRB2, E is Western blot quantification analysis, and 3TC is shown to reduce the number of Formaldehyde (FA) -induced HT22 neuronal cell death by inhibiting LINE-1 and activating the marker proteins of the Estrogen (EGFR), PI3K/Akt (pAKT1) and the neuroactive ligand-receptor interaction (ADRB2) signaling pathway.
Detailed Description
The following further description of the present disclosure is provided in conjunction with the specific drawings and the specific examples, which should not be construed as limiting the present disclosure. The animals, cells, reagents, methods and apparatus used in the examples described below are conventional reagents, methods and apparatus in the art and are commercially available, unless otherwise specified.
Example 1
3TC treatment of SAMP8 in AD model mice
(1) Experimental groups, 44-week-old normal SAMR1 mice as healthy controls, untreated SAMP8 mice as AD model group, and 3TC gavage SAMP8 mice as 3TC treatment group.
(2) Drug treatment, healthy control group (SAMR1+ Vehicle) and AD model group (SAMP8+ Vehicle) were subjected to drinking water gavage daily, and treatment group (SAMP8+3TC) was subjected to 3TC (dissolved in drinking water) gavage at a dose of 100mg/kg for 4 weeks.
Example 2 three groups of mice were simultaneously subjected to the Morris water maze test under the same conditions
(1) And (5) performing directional navigation experiments. The water maze is a circular pool (120 cm diameter with 10 cm diameter circular platform) with water temperature 25 + -1 deg.C. Mice were trained to find a platform below the water surface in one minute. If the mouse does not find a platform within 60s, it is guided to the platform and allowed to stay for 20 s. Each mouse was trained five times a day, with each mouse experiment being 15 minutes apart. In each experiment, the mice had entry initiation sites randomly distributed within four quadrants. The time from entry to landing of the platform for each training was recorded for each mouse as the escape latency.
(2) And (4) carrying out space exploration experiments. On the sixth day of the test, the platform was removed and the mouse entered the water maze from a point opposite the platform. The time for the mouse to explore the maze was set to 60s, and the experiment was terminated after 60 s. The mouse swimming path, speed and time spent in the maze search were recorded by a video camera and analyzed using Ethovision XT (Noldus software).
The results show that:
the escape latency of SAMR1 mice was significantly lower than that of SAMP8 mice (P <0.05) (fig. 1A-B). However, on day 3 and day 5, the escape latency of 3TC treated mice was significantly shorter than that of AD model group (P <0.05), but the difference was not statistically significant compared to healthy control group (P > 0.05). While the mice with 3 TC-dosed SAMP8 swim significantly faster on the first day than the other two groups, no significant difference was detected between the three experimental groups in the next four-day experiment (fig. 1C). The results at day 6 showed that both healthy control and 3TC treated mice stayed more in the target zone than AD model (P <0.05, fig. 1D-E), indicating that both healthy control and 3TC treated mice stayed more in the target quadrant than AD model (P <0.05, fig. 1D-E). In addition, the crossing times of healthy control mice and 3TC treated SAMP8 group mice were also significantly greater than those of AD model group (P <0.05, fig. 1F). Mice in the 3TC treated group had the longest latency to find the platform underwater, and the difference was statistically significant compared to the untreated group (P <0.05, fig. 1G). Data were expressed as mean ± standard error (mean ± SE) using Student's t-test, with 10 samples per group. P <0.05 is statistically different: p <0.001, P <0.01, P < 0.05.
In summary, 3TC treatment can improve the learning and memory function of SAMP8 mice.
Example 3
Example 1 post-experiment mouse brain Paraffin sectioning and tissue staining
(1) And (5) making a paraffin section of the brain. After treatment, mice were anesthetized with 5% diethyl ether and brains were collected after cardiac perfusion with Phosphate Buffered Saline (PBS) and 4% paraformaldehyde solution. Brain tissue was removed and fixed in paraformaldehyde for more than 2 days. The fixed brain was embedded in paraffin. After paraffin is fixed, the paraffin is sliced, and the paraffin mass is sliced into 4-5 mu m paraffin sections.
(2) Hematoxylin-eosin (HE) staining analyzed brain morphological changes. Taking paraffin sections of hippocampal tissues, and performing gradient dewaxing dehydration by using ethanol with a series of concentrations. HE staining was performed using HE staining kit (Solarbio, beijing, china) according to the manufacturer's instructions. After soaking in ethanol and xylene, the sections were fixed with resin and observed under an optical microscope (olympus, tokyo, japan).
(3) And detecting the neuron damage condition on the hippocampal tissue section by adopting a Niger staining method. The sections were incubated with Nisshin staining solution (Hangzhou, Biyuntian) for 30min and washed with 95% ethanol. Stained cells were counted under an optical microscope (olympus, tokyo, japan) and photographed. At random 3 non-overlapping fields were selected on each slide of hippocampal tissue for cell counting, healthy neuron index ═ normal neuron number/total neuron number of nissl bodies.
(4) TUNEL staining. Hippocampal tissue sections were incubated with proteinase K solution for 15min, followed by TUNEL reaction mixture for 30min (Beyotime, China). After three PBS washes, sections were treated with blocking solution containing the nuclear dye DAPI, and TUNEL staining positive (apoptotic) cells were observed and recorded using confocal laser fluorescence microscopy.
The results show that:
compared with a healthy control group, the mice in the AD model group have increased loss of hippocampal neurons, mild disorder of cell arrangement, partial neuron nucleus concentration and mild hippocampal edema. These lesions were improved in the 3TC treated group (fig. 2A). Nissel staining revealed loss of Nissl-positive nerve cells in the AD model group, and partial reversal of the above changes in the 3TC group (FIGS. 2B-C). TUNEL staining showed significantly less hippocampal apoptosis in 3TC treated mice than AD model (P <0.001, fig. 2D-E). Data were expressed as mean ± standard error (mean ± SE) using Student's t-test, with 5 samples per group. P <0.05 is statistically different: p < 0.001.
In summary, 3TC treatment can reduce neuronal damage in the hippocampal region of the brain of SAMP8 mice.
Example 4 mouse brain Hippocampus and cortical tissue RNA extraction and Real-time PCR
After the treatment, the mouse brain hippocampus and cortex tissue RNA was extracted by Trizol (Life technologies) method, and the specific operation was performed according to the instruction. Mu.g of total RNA was added with 2. mu.l of 5 XPrimeScript RT Master Mix (Takara), and the amount of the mixture was adjusted to 20. mu.l with deionized water for reverse transcription to synthesize cDNA; real-time PCR was performed using the set-up program with the primers listed in Table 1.
TABLE 1 Real-time PCR primer sequences
Example 5 network pharmacological analysis to find potential targets for 3TC
(1) And constructing a 3TC target data base. First, the potential target of 3TC was determined using a reverse pharmacophore profile based on the Pharmmapper database. All chemical components were converted to ". mol 2" format by chembidraw and uploaded to the pharmmmapper database. Molecules with normalized fit scores greater than 4.0 were identified as potential targets for 3 TC. Second, the CHEMBL database is used to query the biological activity of the target or compound. Proteins that were shown to be derived from homo sapiens were identified as potential targets for 3 TC.
(2)3TC target protein interaction analysis and core target screening. The selected target protein was analyzed for protein-protein interaction by String9.1 to generate a protein network interaction map. After eliminating duplicates, proteins with confidence scores >0.4 were selected in the designed set for interaction analysis. To fully study the molecular mechanism of 3TC, PPI networks were constructed using Cytoscape software version 3.6.0. Node Degree analysis was performed using centroscope 2.2 to screen the core genes in the network, with the proximity center value (Closeness center value), Betweenness center value (Betweenness center value), and Degree center value (Degree center value) set to 0.2, 450, and 50, respectively.
(3) GO and KEGG analysis. Gene Ontology (GO) enrichment analysis was performed based on the DAVID bioinformatics database using the molecular functions of biological processes, cellular components and potential targets for biological function annotation. The KEGG metabolic pathways were annotated using an online KEGG automated annotation server (http:// www.genome.jp/KEGG /) according to the Gene and genome encyclopedia (KEGG) database of the Kyoto protocol.
(4)3 TC-target molecule docking model construction. Retrieving and obtaining an SDF structure file of a compound 3TC through a pubchem website, converting the SDF file into a PDB file by utilizing Open Babel 2.3.2 software, retrieving and obtaining receptor proteins ADRB2(PDBID:3KJ6), AKT1(PDBID:4EKL) and EGFR (PDBID:6S9C) from a Protein Data Bank (http:// www.rcsb.org/PDB) database, performing operations such as dehydration and ligand removal on the receptor proteins by utilizing PYMOL 2.3.4 software, performing modification such as hydrogenation, charge balance and the like on the four receptor proteins by utilizing AutoDocktools, opening a Grid operation tool by utilizing a Grid Box command under a Grid program, determining the size of a ligand binding pocket by the number and the Grid point interval in each direction, adjusting the Grid point number in each direction of each Protein, the center of the binding pocket and the interval of the Grid point, setting the interval as1, adjusting the interval of the Grid point in each direction, and enabling the volume of the binding pocket to rotate in a state of the joint in which molecules can be in a stretching state, the pocket center is set as the center of the binding site, the receptor protein and the ligand small molecule are respectively converted into pdbqt format, and the three receptor proteins and the 3TC ligand small molecule are respectively subjected to molecular docking by utilizing AutoDock Vina 1.1.2.
The results of examples 4 and 5 show that:
in the hippocampus (fig. 3A), compared to the healthy control group, the transposons LINE-1-associated gene (L1-ORF1, P <0.05), three interferon-responsive genes (IFNA, IRF7 and Oas1, P <0.05), two AD-associated genes (PS-1 and APP, P <0.01), and three representative senescence-associated secretory phenotype genes (IL6, Mmp3, and PAI1, P <0.01) were significantly up-regulated in the AD model group, while the 3TC treatment group significantly down-regulated included one transposon-associated gene (L1-ORF2, P <0.001), two interferon-responsive genes (IFNA and Oas1, P <0.001), and three representative senescence-associated secretory phenotype-associated genes (IL6, Mmp3, PAI1, P < 0.01). Similar results were obtained with experiments on cortical tissues (fig. 3B).
Results of cyber pharmacological analysis show that a total of 269 proteins are predicted targets of 3TC, 164 proteins are identified in the Pharmmapper database, and 105 proteins are identified in the ChEMBL database. Based on the target gene of 3TC, PPI network was constructed using String database, and there are 32 core nodes in the network, which were identified as key targets of 3TC in SAMP8 mouse (fig. 4A). We used String9.1 to mimic the interaction between 3TC key target proteins, thereby identifying three groups of functionally similar proteins (fig. 4B).
GO enrichment analysis of target genes identified under 3TC treatment with STRING revealed a total of 550 biological processes (P <0.05, fig. 5A), such as reactions to acidic chemicals, reactions to reactive oxygen species, and negative control of apoptotic processes. The 3TC target network metabolic pathway KEGG analysis found that three pathways associated with neuroinflammation, cell death and neuronal signal transduction include the estrogen signaling pathway (P <0.0001), the phosphatidylinositol 3-kinase and protein kinase B (PI3K/Akt) signaling pathway (P <0.0001) and the neuroactive ligand-receptor interaction signaling pathway (P <0.001) (fig. 5B).
The 3TC was subjected to molecular docking simulation studies with three selected potential targets, namely EGFR for the estrogen signaling pathway, AKT1 for the P13K/AKT signaling pathway, ADRB2 for the neuroactive ligand-receptor interaction signaling pathway (fig. 5C). The binding mode between the receptor protein ADRB2 and the 3TC ligand small molecule is that amino acid residues Asp331, Phe332 and 3TC form hydrogen bond interaction, and amino acid residues Phe336, Ala335, Val54, Ala57, Ile58, Leu64, Asn69, Ile72, Pro330 and 3TC form hydrophobic interaction; the binding mode between the receptor protein AKT1 and the 3TC ligand small molecule is that amino acid residues Asp292, Glu191, His194, Glu198 and Thr195 and 3TC form hydrogen bond interaction, and amino acid residues Phe179, Leu295, Glu198 and Lys179 and 3TC form hydrophobic interaction; the binding pattern between the receptor protein EGFR and the 3TC ligand small molecule is that amino acid residues Thr854, Asn842, Arg841, Glu762 form hydrogen bond interactions with 3TC, and amino acid residues Lys55, Val40, Ala53, Met111, Val158, Asn114, Leu168, Ser155, Asp169, Lys153, Asn156, Gly35 form hydrophobic interactions with 3 TC.
Example 6 in vitro experiments to verify 3TC action targets
(1) And (3) constructing an in vitro AD-neuron damaged cell model. Mouse hippocampal neural cell line HT22 was purchased from Shanghai cell Biotech. HT22 cells were cultured in DMEM supplemented with 10% Fetal Bovine Serum (FBS). Cells were seeded in 6-well plates 1 day before the experiment and cell damage was induced with Formaldehyde (FA) purchased from Sigma-Aldrich, usa. HT22 cells were divided into 3 groups, the FA group was treated with 30mol/L FA for 24h, the FA +3TC group was treated with 30mol/L FA and 50 mol/L3 TC, and the control group was untreated.
(2) Immunofluorescent staining and cell counting. The culture medium was aspirated off, and the cells were fixed with 2% paraformaldehyde solution at room temperature for 1 h. Immunofluorescence assay procedures were performed according to standard procedures. The antibodies used in this example included anti-LINE-1 ORF1p antibody (1: 1000; Sigma-Aldrich) and Alexa Fluor 594 secondary antibody (1: 1000; Invitgen). Nuclei were labeled by incubation with DAPI (1: 500 dilution; Thermo Fisher Science) for 1 min. After adding the anti-fluorescence quenching mounting agent, the cells were observed and counted with a confocal microscope (nikon, tokyo, japan).
(3) Western blot was used to detect the expression of EGFR, p-AKT1 (active Akt 1: S473 phosphorylates) and ADRB 2. Total protein was collected from the cells after various treatments. Western blot experimental procedures were performed according to standard procedures. The antibodies used in this example include anti-EGFR antibody (1: 500; Sigma-Aldrich), anti-pAKT 1 antibody (1: 1000; Sigma-Aldrich), anti-ADRB 2 antibody (1: 200; Sigma-Aldrich), and anti-rabbit secondary antibody (1: 1000; Invitgen). After washing, the cells were visualized using an ECL Western blotting detection System (amersham, Aylesbury, UK).
The results showed that LINE-1 was activated in damaged neurons and that 3TC reversed this trend (fig. 6A-B) and furthermore, 3TC antagonized FA-induced cell death (fig. 6C). After 24h of FA stimulation of TH22 cells, the expression of EGFR, P-AKT1 and ADRB2 was significantly reduced (P <0.001), whereas after 3TC treatment, the expression of EGFR, P-AKT1 and ADRB2 was significantly increased (P < 0.001; FIG. 6D, E). Data were expressed as mean ± standard error (mean ± SE) using Student's t-test, with 5 samples per group. P <0.05 is statistically different. Black asterisks compared to control, red asterisks compared to FA group: p < 0.001.
The verification results of the above embodiments can be combined to prove that: after the administration of 3TC through gastric gavage on SAMP8 of an AD model mouse, the memory and learning capacity of an SAMP8 mouse are improved, and the inventor finds that 3TC can reduce the number of dead neurons in the hippocampal brain region of the SAMP8 mouse and can reverse the tendency of excessive rise of transposon LINE-1 and type 1 interferon reaction, aging-related secretion phenotype and AD-related pathogenic gene mRNA level in the hippocampal brain and cortical tissues of the SAMP8 mouse. Results of network pharmacological analysis and in vitro experimental validation against 3TC indicate that 3TC can act by activating estrogen, PI3K/Akt and neuroactive ligand-receptor interaction signaling pathways. The results show that the 3TC can obviously improve AD symptoms and brain pathological injury through inhibiting inflammation, apoptosis and other ways, can be developed as a new anti-AD medicament, and provides a new means and way for treating cognitive decline and neuron injury caused by AD.
Claims (2)
1. Application of lamivudine in preparing medicament for treating Alzheimer disease is provided.
2. A medicament for the treatment of alzheimer's disease characterized by: the main active component is lamivudine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110514200.9A CN113134003A (en) | 2021-05-11 | 2021-05-11 | Application of lamivudine in preparation of medicine for treating Alzheimer's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110514200.9A CN113134003A (en) | 2021-05-11 | 2021-05-11 | Application of lamivudine in preparation of medicine for treating Alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113134003A true CN113134003A (en) | 2021-07-20 |
Family
ID=76816946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110514200.9A Pending CN113134003A (en) | 2021-05-11 | 2021-05-11 | Application of lamivudine in preparation of medicine for treating Alzheimer's disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113134003A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108635358A (en) * | 2018-06-15 | 2018-10-12 | 中国农业科学院兰州畜牧与兽药研究所 | Aspirin eugenol ester is preparing the application in preventing or treating Alzheimer disease drugs |
US20190262341A1 (en) * | 2015-02-26 | 2019-08-29 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
WO2020185676A1 (en) * | 2019-03-08 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
US20210106586A1 (en) * | 2019-01-25 | 2021-04-15 | Brown University | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders |
-
2021
- 2021-05-11 CN CN202110514200.9A patent/CN113134003A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190262341A1 (en) * | 2015-02-26 | 2019-08-29 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
CN108635358A (en) * | 2018-06-15 | 2018-10-12 | 中国农业科学院兰州畜牧与兽药研究所 | Aspirin eugenol ester is preparing the application in preventing or treating Alzheimer disease drugs |
US20210106586A1 (en) * | 2019-01-25 | 2021-04-15 | Brown University | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders |
WO2020185676A1 (en) * | 2019-03-08 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rong et al. | Amentoflavone affects epileptogenesis and exerts neuroprotective effects by inhibiting NLRP3 inflammasome | |
Islam et al. | A microRNA signature that correlates with cognition and is a target against cognitive decline | |
Shi et al. | Potential clinical value of circular RNAs as peripheral biomarkers for the diagnosis and treatment of major depressive disorder | |
Yi et al. | RETRACTED ARTICLE: Downregulated lncRNA CRNDE contributes to the enhancement of nerve repair after traumatic brain injury in rats | |
Zhang et al. | Increased EphA4-ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype | |
Han et al. | Effects of CREB1 gene silencing on cognitive dysfunction by mediating PKA-CREB signaling pathway in mice with vascular dementia | |
Li et al. | Lamivudine improves cognitive decline in SAMP8 mice: Integrating in vivo pharmacological evaluation and network pharmacology | |
Lin et al. | Neurogranin as an important regulator in swimming training to improve the spatial memory dysfunction of mice with chronic cerebral hypoperfusion | |
Geng et al. | RNA sequencing analysis of long non-coding RNA expression in ocular posterior poles of guinea pig myopia models | |
Chen et al. | Identification of Functional CircRNA–miRNA–mRNA Regulatory Network in Dorsolateral Prefrontal Cortex Neurons of Patients With Cocaine Use Disorder | |
Levinstein et al. | Stress induces divergent gene expression among lateral habenula efferent pathways | |
Chen et al. | Loss-of-function of KMT5B leads to neurodevelopmental disorder and impairs neuronal development and neurogenesis | |
Li et al. | Regulatory variant rs2535629 in ITIH3 intron confers schizophrenia risk by regulating CTCF binding and SFMBT1 expression | |
Jia et al. | Effects on Autophagy of Moxibustion at Governor Vessel Acupoints in APP/PS1double‐Transgenic Alzheimer’s Disease Mice through the lncRNA Six3os1/miR‐511‐3p/AKT3 Molecular Axis | |
Feng et al. | N6-methyladenosine profiling reveals that Xuefu Zhuyu decoction upregulates METTL14 and BDNF in a rat model of traumatic brain injury | |
CN113134003A (en) | Application of lamivudine in preparation of medicine for treating Alzheimer's disease | |
Zhang et al. | Transcriptome sequencing reveals aerobic exercise training-associated lncRNAs for improving Parkinson’s disease | |
Yao et al. | Scutellaria baicalensis Georgi stems and leaves flavonoids promote neuroregeneration and ameliorate memory loss in rats through cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis | |
Patterson et al. | Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils | |
Bai et al. | Single‐nucleus RNA sequencing unveils critical regulators in various hippocampal neurons for anti‐N‐methyl‐D‐aspartate receptor encephalitis | |
Hong et al. | Integrative analysis identifies region-and sex-specific gene networks and Mef2c as a mediator of anxiety-like behavior | |
Zhang et al. | Construction and comprehensive analysis of a lncRNA–mRNA interactive network to reveal a potential lncRNA for hepatic encephalopathy development | |
Trivedi et al. | Interpretable deep learning framework towards understanding molecular changes in human brains with Alzheimer’s disease: implication for microglia activation and sex differences in AD | |
Sun et al. | Spatiotemporal transcriptomic profiling and modeling of mouse brain at single-cell resolution reveals cell proximity effects of aging and rejuvenation | |
CN115116561B (en) | Application of drug-target protein-schizophrenia interaction network |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210720 |